Cover Image
市場調查報告書

癌症生物標記的全球市場 - 產業分析·市場規模·市場佔有率·成長率·各種趨勢·未來預測:檢驗類型 (PSA·CTC、AFP·CA·HER2·BRCA·ALK·CEA·EGFR變異·KRA變異檢驗)·各疾病

Cancer Biomarkers Market (Test Type - PSA, CTC, AFP, CA, HER2, BRCA, ALK, CEA, EGFR Mutation, & KRAS Mutation Tests; Disease Indication) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

出版商 Transparency Market Research 商品編碼 512167
出版日期 內容資訊 英文 157 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症生物標記的全球市場 - 產業分析·市場規模·市場佔有率·成長率·各種趨勢·未來預測:檢驗類型 (PSA·CTC、AFP·CA·HER2·BRCA·ALK·CEA·EGFR變異·KRA變異檢驗)·各疾病 Cancer Biomarkers Market (Test Type - PSA, CTC, AFP, CA, HER2, BRCA, ALK, CEA, EGFR Mutation, & KRAS Mutation Tests; Disease Indication) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
出版日期: 2017年05月10日 內容資訊: 英文 157 Pages
簡介

本報告提供全球癌症生物標記的市場調查,提供市場及產品定義和概要,市場成長的各種影響因素及市場機會分析,檢驗類型·疾病區分·地區/各主要國家趨勢與市場規模的變化與預測,競爭環境,並彙整主要企業的簡介等資訊。

第1章 序章

第2章 前提條件·調查手法

第3章 摘要整理

第4章 市場概要

  • 簡介 (產品定義)
  • 產業的發展
  • 主要市場指標
  • 市場動態
    • 成長推進因素
    • 阻礙成長要素
    • 市場機會
  • 全球市場分析·預測
  • 全球供需方案
  • 波特的五力分析
  • 市場展望
  • 癌症的流行病學

第5章 市場分析·預測:檢驗類別

  • 主要調查結果
  • 簡介
  • 市場規模的預測
    • PSA檢驗
    • CTC檢驗
    • AFP檢驗
    • CA檢驗
    • HER2檢驗
    • BRCA檢驗
    • ALK檢驗
    • CEA檢驗
    • EGFR變異檢驗
    • KRAS變異檢驗
    • 其他
  • 市場魅力分析
  • 主要趨勢

第6章 市場分析·預測:各疾病

  • 主要調查結果
  • 簡介
  • 市場規模的預測
    • 乳癌
    • 肺癌
    • 大腸癌
    • 黑色素瘤
    • 血液癌症
    • 前列腺癌
    • 卵巢癌
    • 胃癌
    • 肝癌症
    • 其他
  • 市場魅力分析
  • 主要趨勢

第7章 市場分析·預測:各地區

  • 主要調查結果
  • 簡介

第8章 北美市場分析·預測

  • 主要調查結果
  • 市場預測:檢驗類別
  • 市場預測:各疾病
  • 市場預測:各國
    • 美國
    • 加拿大
  • 市場魅力分析
  • 市場趨勢

第9章 歐洲的市場分析·預測

  • 主要調查結果
  • 市場預測:檢驗類別
  • 市場預測:各疾病
  • 市場預測:各國
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 市場魅力分析
  • 市場趨勢

第10章 亞太地區市場分析·預測

  • 主要調查結果
  • 市場預測:檢驗類別
  • 市場預測:各疾病
  • 市場預測:各國
    • 印度
    • 中國
    • 日本
    • 澳洲&紐西蘭
    • 其他
  • 市場魅力分析
  • 市場趨勢

第11章 南美市場分析·預測

  • 主要調查結果
  • 市場預測:檢驗類別
  • 市場預測:各疾病
  • 市場預測:各國
    • 巴西
    • 墨西哥
    • 其他
  • 市場魅力分析
  • 市場趨勢

第12章 中東·非洲市場分析·預測

  • 主要調查結果
  • 市場預測:檢驗類別
  • 市場預測:各疾病
  • 市場預測:各國
    • 南非
    • GCC各國
    • 其他
  • 市場魅力分析
  • 市場趨勢

第13章 競爭環境

  • 企業佔有率分析
  • 競爭矩陣
  • 企業簡介
    • Abbott Laboratories
    • Merck & Co., Inc.
    • Thermo Fisher Scientific Inc
    • Illumina, Inc.
    • bioMerieux SA
    • QIAGEN
    • Agilent Technologies, Inc.
    • Hologic, Inc.
    • Novartis AG
    • F. Hoffmann-La Roche Ltd.
    • Genomic Health, Inc.

圖表

目錄

Title:
Cancer Biomarkers Market
(Test Type - PSA Tests, CTC Tests, AFP Tests, CA Tests, HER2 Tests, BRCA Tests, ALK Tests, CEA Tests, EGFR Mutation Tests, and KRAS Mutation Tests; Disease Indication - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Blood Cancer, Prostate Cancer, Ovarian Cancer, Stomach Cancer, and Liver Cancer) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025.

Global Cancer Biomarkers Market: Overview

Biomarkers are the substance or molecules found in blood, other body fluids or tissues which states the normal and abnormal condition of the body, biomarkers helps to detect various diseases such as cancer. Cancer biomarkers tests are carried out to detect genes or mutated genes responsible for cancer. Dramatic improvement in the cancer biomarkers tests will increase demand globally.

A detailed overview of market dynamics, including the drivers, restraints, and opportunities of the cancer biomarkers market, has been provided in this report. Market revenue for all the above mentioned segments, and their sub segments has been provided for the forecast period of 2017-2025, considering 2016 as the base year, and 2015 as the historical year, along with compound annual growth rate (CAGR %), for the forecast period of 2017-2025. Market share estimations were based on in-depth analysis and study of products, and their features, prices etc.

This report provides in-depth analysis of the cancer biomarkers market. The stakeholders for this report include companies involved in the reagent manufacturer for cancer biomarkers tests. For providing a snapshot of this market to the stakeholders, executive summary section is included in this report, which summarizes the market size, trends and competition in different regions. Market share analysis among the market players is analyzed to signify percentage share of the major players operating in the cancer biomarkers market. Furthermore, the report incorporates market attractiveness analysis by geography that depicts the most attractive and significant region in the global market in 2015.

The research methodology is a combination of primary and secondary research. Primary research includes information collected via e-mails, and telephonic interviews of Key Opinion Leaders (KOL), and forms the bulk of our research. Secondary research includes information collected from various sources, by study of company websites, annual reports, stock analysis presentations, press releases, and various national and international databases.

Global Cancer Biomarkers Market: Segmentation

Based on test type, global cancer biomarkers market are segmented into PSA tests, CTC tests, AFP tests, CA tests, HER2 tests, BRCA tests, ALK tests, CEA tests, EGFR Mutation tests, KRAS Mutation tests and others. Based on disease indication, the cancer biomarkers market are segmented into breast cancer, lung cancer, colorectal cancer, melanoma, blood cancer, prostate cancer, ovarian cancer, stomach cancer, liver cancer and others.

Based on geography, the cancer biomarkers market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The regions are further segmented into major countries which include, U.S., Canada, Germany, U.K., France, Spain, Italy, Russia, rest of Europe, India, China, Japan, Australia and New Zealand, Rest of Asia Pacific, Brazil, Mexico, Rest of Latin America, GCC countries, South Africa and Rest of Middle East and Africa.

Companies Mentioned in the Report

The report also comprises list major players in the market, their SWOT analysis, market share of these players in the cancer biomarkers, key business strategies, product portfolios, and recent developments. Key market players profiled in this report include, Abbott Laboratories, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Illumina, Inc., Agilent Technologies, QIAGEN, Merck & Co., Inc., Hologic, Inc., Novartis AG, bioMerieux SA, Genomic Health, Inc. and others

The global cancer biomarkers market has been segmented as follows:

Global Cancer Biomarkers Market, by Test Type

  • PSA Tests
  • CTC Tests
  • AFP Tests
  • CA Tests
  • HER2 Tests
  • BRCA Tests
  • ALK Tests
  • CEA Tests
  • EGFR Mutation Tests
  • KRAS Mutation Tests
  • Others

Global Cancer Biomarkers Market, by Disease Indication

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Melanoma
  • Blood Cancer
  • Prostate Cancer
  • Ovarian Cancer
  • Stomach Cancer
  • Liver Cancer
  • Others

Global Cancer Biomarkers Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC countries
    • South Africa
    • Rest of MEA

Table of Contents

1. Preface

2. Research Methodology & Assumptions

3. Executive Summary

4. Global Cancer Biomarkers Products Market Overview

  • 4.1. Introduction (Product Definition)
  • 4.2. Industry Evolution/Development
  • 4.3. Key Market Indicators
  • 4.4. Market Dynamics
    • 4.4.1. Drivers
    • 4.4.2. Restraints
    • 4.4.3. Opportunity
  • 4.5. Global Cancer Biomarkers Market Analysis and Forecasts, 2015-2025
  • 4.6. Cancer Biomarkers Market-Global Supply Demand Scenario
  • 4.7. Porter's Five Force Analysis
  • 4.8. Market Outlook
  • 4.9. Cancer Epidemiology, by region

5. Global Cancer Biomarkers Market Analysis and Forecast by Test Type

  • 5.1. Key Findings
  • 5.2. Introduction
  • 5.3. Market Size (US$ Mn) Forecast, By Test Type
    • 5.3.1. PSA Tests
    • 5.3.2. CTC Tests
    • 5.3.3. AFP Tests
    • 5.3.4. CA Tests
    • 5.3.5. HER2 Tests
    • 5.3.6. BRCA Tests
    • 5.3.7. ALK Tests
    • 5.3.8. CEA Tests
    • 5.3.9. EGFR Mutation Tests
    • 5.3.10. KRAS Mutation Tests
    • 5.3.11. Others
  • 5.4. Market Attractiveness, By Test Type
  • 5.5. Key Trends

6. Global Cancer Biomarkers Market Analysis and Forecast by Disease Indication

  • 6.1. Key Findings
  • 6.2. Introduction
  • 6.3. Market Size (US$ Mn) Forecast, By Disease Indication
    • 6.3.1. Breast Cancer
    • 6.3.2. Lung Cancer
    • 6.3.3. Colorectal Cancer
    • 6.3.4. Melanoma
    • 6.3.5. Blood Cancer
    • 6.3.6. Prostate Cancer
    • 6.3.7. Ovarian Cancer
    • 6.3.8. Stomach Cancer
    • 6.3.9. Liver Cancer
    • 6.3.10. Others
  • 6.4. Market Attractiveness, By Disease Indication
  • 6.5. Key Trends

7. Global Cancer Biomarkers Market Analysis and Forecast by Region

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Market Size (US$ Mn) Forecast, By Region
    • 7.2.2. North America
    • 7.2.3. Europe
    • 7.2.4. Asia Pacific
    • 7.2.5. Latin America
    • 7.2.6. Middle East and Africa

8. North America Cancer Biomarkers Market Analysis and Forecast by Region

  • 8.1. Key Findings
  • 8.2. North America Cancer Biomarkers Market Forecast, by Test Type
  • 8.3. North America Cancer Biomarkers Market Forecast, by Disease Indication
  • 8.4. North America Cancer Biomarkers Market Forecast, by Country
    • 8.4.1. U.S. Cancer Biomarkers Market Overview
    • 8.4.2. Canada Cancer Biomarkers Market Overview
  • 8.5. North America Market Attractiveness Analysis
  • 8.6. Market Trends

9. Europe Cancer Biomarkers Market Analysis and Forecast by Region

  • 9.1. Key Findings
  • 9.2. Europe Cancer Biomarkers Market Forecast, by Test Type
  • 9.3. Europe Cancer Biomarkers Market Forecast, by Disease Indication
  • 9.4. Europe Cancer Biomarkers Market Forecast, by Country
    • 9.4.1. U.K. Cancer Biomarkers Market Overview
    • 9.4.2. Germany Cancer Biomarkers Market Overview
    • 9.4.3. France Cancer Biomarkers Market Overview
    • 9.4.4. Italy Cancer Biomarkers Market Overview
    • 9.4.5. Spain Cancer Biomarkers Market Overview
    • 9.4.6. Russia Cancer Biomarkers Market Overview
    • 9.4.7. Rest of Europe Cancer Biomarkers Market Overview
  • 9.5. Europe Market Attractiveness Analysis
  • 9.6. Market Trends

10. Asia Pacific Cancer Biomarkers Market Analysis and Forecast by Region

  • 10.1. Key Findings
  • 10.2. Asia Pacific Cancer Biomarkers Market Forecast, by Test Type
  • 10.3. Asia Pacific Cancer Biomarkers Market Forecast, by Disease Indication
  • 10.4. Asia Pacific Cancer Biomarkers Market Forecast, by Country
    • 10.4.1. India Cancer Biomarkers Market Overview
    • 10.4.2. China Cancer Biomarkers Market Overview
    • 10.4.3. Japan Cancer Biomarkers Market Overview
    • 10.4.4. Australia & New Zealand Cancer Biomarkers Market Overview
    • 10.4.5. Rest of APAC Cancer Biomarkers Market Overview
  • 10.5. Asia Pacific Market Attractiveness Analysis
  • 10.6. Market Trends

11. Latin America Cancer Biomarkers Market Analysis and Forecast by Region

  • 11.1. Key Findings
  • 11.2. Latin America Cancer Biomarkers Market Forecast, by Test Type
  • 11.3. Latin America Cancer Biomarkers Market Forecast, by Disease Indication
  • 11.4. Latin America Cancer Biomarkers Market Forecast, by Country
    • 11.4.1. Brazil Cancer Biomarkers Market Overview
    • 11.4.2. Mexico Cancer Biomarkers Market Overview
    • 11.4.3. Rest of LATAM Cancer Biomarkers Market Overview
  • 11.5. Latin America Market Attractiveness Analysis
  • 11.6. Market Trends

12. Middle East and Africa Cancer Biomarkers Market Analysis and Forecast by Region

  • 12.1. Key Findings
  • 12.2. Middle East and Africa Cancer Biomarkers Market Forecast, by Test Type
  • 12.3. Middle East and Africa Cancer Biomarkers Market Forecast, by Disease Indication
  • 12.4. Middle East and Africa Cancer Biomarkers Market Forecast, by Country
    • 12.4.1. South Africa Cancer Biomarkers Market Overview
    • 12.4.2. GCC countries Cancer Biomarkers Market Overview
    • 12.4.3. Rest of MEA Cancer Biomarkers Market Overview
  • 12.5. Middle East and Africa Market Attractiveness Analysis
  • 12.6. Market Trends

13. Competitive Landscape

  • 13.1. Market Share Analysis, by Company
  • 13.2. Competition Matrix
  • 13.3. Company Profiles
    • 13.3.1. Abbott Laboratories
      • 13.3.1.1. Company Details
      • 13.3.1.2. Business Overview
      • 13.3.1.3. Financial Overview
      • 13.3.1.4. Strategic Overview
      • 13.3.1.5. SWOT Analysis
    • 13.3.2. Merck & Co., Inc.
      • 13.3.2.1. Company Details
      • 13.3.2.2. Business Overview
      • 13.3.2.3. Financial Overview
      • 13.3.2.4. Strategic Overview
      • 13.3.2.5. SWOT Analysis
    • 13.3.3. Thermo Fisher Scientific Inc
      • 13.3.3.1. Company Details
      • 13.3.3.2. Business Overview
      • 13.3.3.3. Financial Overview
      • 13.3.3.4. Strategic Overview
      • 13.3.3.5. SWOT Analysis
    • 13.3.4. Illumina, Inc.
      • 13.3.4.1. Company Details
      • 13.3.4.2. Business Overview
      • 13.3.4.3. Financial Overview
      • 13.3.4.4. Strategic Overview
      • 13.3.4.5. SWOT Analysis
    • 13.3.5. bioMerieux SA
      • 13.3.5.1. Company Details
      • 13.3.5.2. Business Overview
      • 13.3.5.3. Financial Overview
      • 13.3.5.4. Strategic Overview
      • 13.3.5.5. SWOT Analysis
    • 13.3.6. QIAGEN
      • 13.3.6.1. Company Details
      • 13.3.6.2. Business Overview
      • 13.3.6.3. Financial Overview
      • 13.3.6.4. Strategic Overview
      • 13.3.6.5. SWOT Analysis
    • 13.3.7. Agilent Technologies, Inc.
      • 13.3.7.1. Company Details
      • 13.3.7.2. Business Overview
      • 13.3.7.3. Financial Overview
      • 13.3.7.4. Strategic Overview
      • 13.3.7.5. SWOT Analysis
    • 13.3.8. Hologic, Inc.
      • 13.3.8.1. Company Details
      • 13.3.8.2. Business Overview
      • 13.3.8.3. Financial Overview
      • 13.3.8.4. Strategic Overview
      • 13.3.8.5. SWOT Analysis
    • 13.3.9. Novartis AG
      • 13.3.9.1. Company Details
      • 13.3.9.2. Business Overview
      • 13.3.9.3. Financial Overview
      • 13.3.9.4. Strategic Overview
      • 13.3.9.5. SWOT Analysis
    • 13.3.10. F. Hoffmann-La Roche Ltd.
      • 13.3.10.1. Company Details
      • 13.3.10.2. Business Overview
      • 13.3.10.3. Financial Overview
      • 13.3.10.4. Strategic Overview
      • 13.3.10.5. SWOT Analysis
    • 13.3.11. Genomic Health, Inc.
      • 13.3.11.1. Company Details
      • 13.3.11.2. Business Overview
      • 13.3.11.3. Financial Overview
      • 13.3.11.4. Strategic Overview
      • 13.3.11.5. SWOT Analysis

List of Table

  • Table 01: Global Cancer Biomarkers Market Size (US$ Mn) Forecast, By Test Type, 2015-2025
  • Table 02: Global Cancer Biomarkers Market Size (US$ Mn) Forecast, By Disease Indication, 2015-2025
  • Table 03: Global Cancer Biomarkers Market Size (US$ Mn) Forecast, By Region Type, 2015 - 2025
  • Table 04: North America Cancer Biomarkers Market Size (US$ Mn) Forecast, By Test Type, 2015-2025
  • Table 05: North America Cancer Biomarkers Market Size (US$ Mn) Forecast, By Disease Indication, 2015-2025
  • Table 06: North America Cancer Biomarkers Market Size (US$ Mn) Forecast, By Country, 2015-2025
  • Table 07: Europe Cancer Biomarkers Market Size (US$ Mn) Forecast, By Test Type, 2015-2025
  • Table 08: Europe Cancer Biomarkers Market Size (US$ Mn) Forecast, By Disease Indication, 2015-2025
  • Table 09: Europe Cancer Biomarkers Market Size (US$ Mn) Forecast, By Country, 2015-2025
  • Table 10: Asia Pacific Cancer Biomarkers Market Size (US$ Mn) Forecast, By Test Type, 2015-2025
  • Table 11: Asia Pacific Cancer Biomarkers Market Size (US$ Mn) Forecast, By Disease Indication, 2015-2025
  • Table 12: Asia Pacific Cancer Biomarkers Market Size (US$ Mn) Forecast, By Country, 2015-2025
  • Table 13: Latin America Cancer Biomarkers Market Size (US$ Mn) Forecast, By Test Type, 2015-2025
  • Table 14: Latin America Cancer Biomarkers Market Size (US$ Mn) Forecast, By Disease Indication, 2015-2025
  • Table 15: Latin America Cancer Biomarkers Market Size (US$ Mn) Forecast, By Country, 2015-2025
  • Table 16: Middle East & Africa Cancer Biomarkers Market Size (US$ Mn) Forecast, By Test Type, 2015-2025
  • Table 17: Middle East & Africa Cancer Biomarkers Market Size (US$ Mn) Forecast, By Disease Indication, 2015-2025
  • Table 18: Middle East & Africa Cancer Biomarkers Market Size (US$ Mn) Forecast, By Country, 2015-2025

List of Figures

  • Figure 01: Global Cancer Biomarkers Market Size (US$ Mn) Forecast, 2016 - 2025
  • Figure 02: Global Cancer Biomarkers Market Value Share Analysis By Test Type, 2017 and 2025
  • Figure 03: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by PSA Tests, 2016-2025
  • Figure 04: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by CTC Tests, 2016-2025
  • Figure 05: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by AFP Tests, 2016-2025
  • Figure 06: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by CA Tests, 2016-2025
  • Figure 07: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by HER2 Tests, 2016-2025
  • Figure 08: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by BRCA Tests, 2016-2025
  • Figure 09: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by ALK Tests, 2016-2025
  • Figure 10: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by CEA Tests, 2016-2025
  • Figure 11: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by EGFR Tests, 2016-2025
  • Figure 12: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by KRAS Mutation Tests, 2016-2025
  • Figure 13: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016-2025
  • Figure 14: Cancer Biomarkers Market Attractiveness Analysis By Test Type
  • Figure 15: Global Cancer Biomarkers Market Value Share Analysis By Disease Indication, 2017 and 2025
  • Figure 16: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Breast Cancer, 2016-2025
  • Figure 17: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Lung Cancer, 2016-2025
  • Figure 18: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Colorectal Cancer, 2016-2025
  • Figure 19: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Melanoma, 2016-2025
  • Figure 20: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Blood Cancer, 2016-2025
  • Figure 21: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Prostate Cancer, 2016-2025
  • Figure 22: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Ovarian Cancer, 2016-2025
  • Figure 23: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Stomach Cancer, 2016-2025
  • Figure 24: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liver Cancer, 2016-2025
  • Figure 25: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016-2025
  • Figure 26: Cancer Biomarkers Market Attractiveness Analysis By Disease Indication
  • Figure 27: Global Cancer Biomarkers Market Value Share Analysis By Region Type, 2017 and 2025
  • Figure 28: Cancer Biomarkers Market Attractiveness Analysis, By Region Type
  • Figure 29: North America Cancer Biomarkers Market Size (US$ Mn) Forecast, 2017 - 2025
  • Figure 30: North America Market Attractiveness Analysis By Country
  • Figure 31: North America Cancer Biomarkers Market Value Share Analysis By Test Type, 2017 and 2025
  • Figure 32: North America Cancer Biomarkers Market Value Share Analysis By Disease Indication, 2017 and 2025
  • Figure 33: North America Market Value Share Analysis By Country, 2017 and 2025
  • Figure 34: North America Market Attractiveness Analysis, By Test Type
  • Figure 35: North America Market Attractiveness Analysis, By Disease Indication
  • Figure 36: Europe Cancer Biomarkers Market Size (US$ Mn) Forecast, 2016 - 2025
  • Figure 37: Europe Market Attractiveness Analysis By Country
  • Figure 38: Europe Cancer Biomarkers Market Value Share Analysis By Test Type, 2017 and 2025
  • Figure 39: Europe Cancer Biomarkers Market Value Share Analysis By Disease Indication, 2017 and 2025
  • Figure 40: Europe Market Value Share Analysis By Country, 2017 and 2025
  • Figure 41: Europe Market Attractiveness Analysis, By Test Type
  • Figure 42: Europe Market Attractiveness Analysis, By Disease Indication
  • Figure 43: Asia Pacific Cancer Biomarkers Market Size (US$ Mn) Forecast, 2016 - 2025
  • Figure 44: Asia Pacific Market Attractiveness Analysis By Country
  • Figure 45: Asia Pacific Cancer Biomarkers Market Value Share Analysis By Test Type, 2017 and 2025
  • Figure 46: Asia Pacific Cancer Biomarkers Market Value Share Analysis By Disease Indication, 2017 and 2025
  • Figure 47: Europe Market Value Share Analysis By Country, 2017 and 2025
  • Figure 48: Asia Pacific Market Attractiveness Analysis, By Test Type
  • Figure 49: Asia Pacific Market Attractiveness Analysis, By Disease Indication
  • Figure 50: Latin America Cancer Biomarkers Market Size (US$ Mn) Forecast, 2016 - 2025
  • Figure 51: Latin America Market Attractiveness Analysis By Country
  • Figure 52: Latin America Cancer Biomarkers Market Value Share Analysis By Test Type, 2017 and 2025
  • Figure 53: Latin America Cancer Biomarkers Market Value Share Analysis By Disease Indication, 2017 and 2025
  • Figure 54: Latin America Market Value Share Analysis By Country, 2017 and 2025
  • Figure 55: Latin America Market Attractiveness Analysis, By Test Type
  • Figure 56: Latin America Market Attractiveness Analysis, By Disease Indication
  • Figure 57: Middle East & Africa Cancer Biomarkers Market Size (US$ Mn) Forecast, 2016 - 2025
  • Figure 58: Middle East & Africa Market Attractiveness Analysis By Country
  • Figure 59: Middle East & Africa Cancer Biomarkers Market Value Share Analysis By Test Type, 2017 and 2025
  • Figure 60: Middle East & Africa Cancer Biomarkers Market Value Share Analysis By Disease Indication, 2017 and 2025
  • Figure 61: Middle East & Africa Market Value Share Analysis By Country, 2017 and 2025
  • Figure 62: Middle East & Africa Market Attractiveness Analysis, By Test Type
  • Figure 63: Middle East & Africa Market Attractiveness Analysis, By Disease Indication
  • Figure 64: Global Cancer Biomarkers Market Share Analysis By Company (2015)
Back to Top